EPISODE · Mar 26, 2025 · 16 MIN
Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer
from Listen to Gynecologic Oncology · host Health Advance
Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort studyEditorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind?Hosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing:Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, Columbus, OH, United States of AmericaRamez N. Eskander, MD, UC San Diego School of Medicine, Moores Cancer Center at UC San Diego Health, San Diego, CACheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
Embed this episode
What this episode covers
Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind? Hosted by: Warner Huh, MD, Deputy Editor of Gynecologic Oncology Featuring: Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics a...
Ready to play
Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.